Biotech

All Articles

Lykos 'disappointments' not revealing research study offenses with author

.Psychopharmacology has actually taken 3 posts about midstage professional test information analyzin...

Analysts examine Avidity's DMD gain, disclosing nuances in information

.Avidity Biosciences amazed investors with stage 1/2 records in Duchenne muscular dystrophy (DMD) Fr...

Actinogen's cortisol blocker falls short phase 2 clinical depression research study

.Actinogen Medical's cortisol blocker has missed out on the primary endpoint of a phase 2 research i...

Bivictrix decides going exclusive only technique to take ADC right into facility

.Antibody-drug conjugates (ADCs) have actually gone to the center of a lot of a billion-dollar biobu...

TPG tops up funds to $580M for assets across life scientific researches

.Resource supervisor TPG, which has sustained biotechs including Sionna Rehabs and also Santa Ana Bi...

Merck quits phase 3 TIGIT trial in lung cancer cells for futility

.Merck &amp Co.'s TIGIT course has gone through one more drawback. Months after shuttering a phase 3...

After a challenging year, Exscientia folds up in to Recursion

.After a year defined by pipe cuts, the departure of its own chief executive officer and cutbacks, E...

Cullinan, after $25M bargain, return bispecific to Port

.Cullinan Therapy was actually wowed good enough along with Port BioMed's bispecific invulnerable re...

A deeper take a look at Strong Biotech's Fierce 15

.In this week's episode of "The Best Line," our company are actually diving in to Brutal Biotech's a...

Lilly faces period 2 failing of tau-targeting med

.The confetti is actually still soaring from Eli Lilly's event celebrating the approval of Alzheimer...